Abstract:Introduction: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that widely affects motor neurons of the CNS. About 20% of patients with ALS have familial ALS (fALS). One of the classic models of ALS are SOD1 G93A mice. Misfolded SOD1 protein can be overexpressed in motor neurons, which results in progressive paralysis of the limbs of mice. There is still no effective treatment for ALS. In recent years, the treatment of ALS by regulating autophagy has become a research hotspot. Autophagy obstacles have been confirmed to be one of the early pathological events of ALS. Rab7 is a member of the Ras superfamily and plays a key role in the late stage of autophagy. In our previous studies, we found that prenoylation of Rab7 was inhibited in the ALS model. Prenylation is a post-translational modification in which farnesyl or geranylgeranyl groups are covalently linked to target proteins. Based on these findings, we proposed the novel idea that the regulation of RabGGTB (the β-subunit of RabGGTase) mediated prenylation modification of Rab7, and that this can be used as a prevention and treatment of ALS associated with abnormal protein accumulation. Methods: In the present study, RabGGTB was overexpressed in mouse spinal cord motoneurons by using adeno-associated virus as vector. Then immunofluorescence quantitative analysis was used for pathological study. The body weight, footprint analysis, the accelerating rotarod test, and neurological deficits score were used to evaluate animal behavior. Results: Our results show that the protein level of RabGGTB was significantly increased in the lumbar and thoracic regions of spinal cord motoneurons of injected mice. Furthermore, the onset time and survival time of SOD1 G93A mice injected with AAV9-RabGGTB-GFP + were delayed compared with those of mice without overexpression. At the same time, we also observed a decrease in SOD1 misfolded and glial overactivation in the lumbar spinal cord of these SOD1 G93A mice. Conclusion: The findings reported here show that RabGGTB plays a significant role in the pathogenesis of SOD1 G93A mice and with great therapeutic potential for reducing abnormal aggregation of SOD1 in ALS.

Intranasal delivery of small extracellular vesicles reduces the progress of amyotrophic lateral sclerosis and the overactivation of complement-coagulation cascade and NF-ĸB signaling in SOD1G93A mice

Combined Intranasal Nerve Growth Factor and Ventricle Neural Stem Cell Grafts Prolong Survival and Improve Disease Outcome in Amyotrophic Lateral Sclerosis Transgenic Mice

ASC-Exosomes Ameliorate the Disease Progression in SOD1(G93A) Murine Model Underlining Their Potential Therapeutic Use in Human ALS

Intravenous infusion of mesenchymal stem cells delays disease progression in the SOD1G93A transgenic amyotrophic lateral sclerosis rat model

Intrathecal delivery of AAV-NDNF ameliorates disease progression of ALS mice

Micro-RNAs Shuttled by Extracellular Vesicles Secreted from Mesenchymal Stem Cells Dampen Astrocyte Pathological Activation and Support Neuroprotection in In-Vitro Models of ALS

Intrathecal delivery of mesenchymal stromal cells protects the structure of altered perineuronal nets in SOD1 rats and amends the course of ALS

Protective effects of intrathecal injection of AAV9-RabGGTB-GFP+ in SOD1G93A mice

Olfactory Ensheathing Cell Transplantation Into Spinal Cord Prolongs The Survival Of Mutant Sod1(G93a) Als Rats Through Neuroprotection And Remyelination

Lipid nanoparticles and transcranial focused ultrasound enhance the delivery of SOD1 antisense oligonucleotides to the murine brain for ALS therapy

A Cellular Model of Amyotrophic Lateral Sclerosis to Study the Therapeutic Effects of Extracellular Vesicles from Adipose Mesenchymal Stem Cells on Microglial Activation

Intrathecal Injection of the Secretome from ALS Motor Neurons Regulated for miR-124 Expression Prevents Disease Outcomes in SOD1-G93A Mice

Extracellular Vesicles from NSC-34 MN-like Cells Transfected with Mutant SOD1 Modulate Inflammatory Status of Raw 264.7 Macrophages

Combination AAV therapy with galectin-1 and SOD1 downregulation demonstrates superior therapeutic effect in a severe ALS mouse model

Neural Stem Cell-Derived Extracellular Vesicles Mitigate Alzheimer’s Disease-Like Phenotypes in a Preclinical Mouse Model

Slowing disease progression in the SOD1 mouse model of ALS by blocking neuregulin-induced microglial activation

Olfactory Ensheathing Cells (oecs) Transplantation in Spinal Cord Prolongs the Survival of Mutant SOD1 (G93A) ALS Rats Through Neuroprotection and Remyelination

Attenuation of amyotrophic lateral sclerosis via stem cell and extracellular vesicle therapy: An updated review

An Oligomer-Specific Antibody Improved Motor Function and Attenuated Neuropathology in the SOD1-G93A Transgenic Mouse Model of ALS

Intranasally Administered EVs from hiPSC-derived NSCs Alter the Transcriptomic Profile of Activated Microglia and Conserve Brain Function in an Alzheimer’s Model

Targeting low levels of MIF expression as a potential therapeutic strategy for ALS